In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar

被引：56

作者：

Bansal D. ^{[1
]}

Sehgal R. ^{[1
]}

Chawla Y. ^{[2
]}

Mahajan R.C. ^{[1
]}

Malla N. ^{[1
]}

机构：

[1] Department of Parasitology, Post Graduate Institute of Medical Education and Research, Chandigarh

[2] Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh

来源：

Annals of Clinical Microbiology and Antimicrobials | / 3卷 / 1期

关键词：

Metronidazole; Clinical Isolate; Reference Strain; Chloroquine; Tinidazole;

D O I：

10.1186/1476-0711-3-27

中图分类号：

学科分类号：

摘要：

Background: Amoebiases is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and E. dispar to metronidazole, chloroquine, emetine and tinidazole. Methods: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC50) of clinical isolates and standard reference strain of E. histolytica (HMI: IMSS) was assessed by nitro blue tetrazolium (NBT) reduction assay after exposure to various concentrations of each drug. Results: The results showed that all clinical isolates had a higher IC50 compared to reference strain to all four drugs. E. histolytica isolates appeared to be more susceptible [IC50 (μm) 13.2,26.3,31.2 and 12.4] compared to E. dispar isolates [IC50(μm) 15.6,28.9,32.8 and 13.2] and the reference strain of E. histolytica [IC50 (μm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and tinidazole respectively. Conclusions: The results indicate that till date, Entamoeba isolates in India do not seem to be resistant to the commonly used antiamoebic drugs. © 2004 Bansal et al; licensee BioMed Central Ltd.

引用

共 19 条

[1]

Walsh J.A., Problems in recognition and diagnosis of amoebiasis: Estimation of the global magnitude of mortality and morbidity, Rev Infect Dis, 8, pp. 228-238, (1986)

[2]

Diamond L.S., Clark C.G., A redescription of Entamoeba histolytica Schaudinn 1903 (emended walker, 1911) separating it from Entamoeba dispar Brumpt, 1925, J Eukaryot Microbiol, 40, pp. 340-344, (1993)

[3]

Martinez-Palomo A., Martinez-Baez M., Selective primary health care: Strategies for control of disease in the developing world X amoebiasis, Rev Infect Dis, 5, pp. 1093-1102, (1983)

[4]

Gomez M.D., Perez D.G., Ayala P., Samuelson J., Orozco E., Physiology and molecular biology of multidrug resistance in Entamoeba histolytica, Arch Med Res, 27, pp. 421-425, (1996)

[5]

Pittman F.E., Pittman J.C., Amoebic liver abscess following metronidazole therapy for amoebic colitis, Am J Trop Med Hyg, 23, pp. 146-150, (1974)

[6]

Burthard G.D., Mirelman D., Entamoeba histolytica virulence potential and sensitivity to metronidazole and emetine of four isolates possessing nonpathogenic zymodemes, Exp Parasitol, 66, pp. 231-242, (1988)

[7]

Upcroft P., Upcroft J.A., Drug targets and mechanisms of resistance in the anaerobic protozoa, Clin Microbiol Rev, 14, pp. 150-164, (2001)

[8]

Aguirre-Cruz M.L., Valadez-Salazar A., Munoz O., In vitro sensitivity of Entamoeba histolytica to metronidazole, Arch Invest Med (Mex), 21, pp. 23-26, (1990)

[9]

Adagu S.I., Noider D., Warhurst D.C., Rossignol J.F., In vitro activity of nitazoxanide and related compounds against isolates of Glardia intestinalis, Entamoeba histolytica, Trichomonas vaginalis, J Antimicrob Chemother, 49, pp. 103-111, (2002)

[10]

Bansal D., Sehgal R., Chawla Y., Mahajan R.C., Malla N., Comparative Evaluation of Hexokinase Isoenzyme Typing and Antigen Detection for Differentiation of Entamoeba histolytica and Entamoeba dispar, Nepal Med Coll J

← 1 2 →